| abstract |
A novel pharmaceutical composition comprising a benzoquinoline compound and a method for inhibiting vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperactivity movement disorder. A pharmaceutical composition comprising a deuterated analog of tetrabenazine, as compared to a pharmaceutical composition comprising the same amount of non-deuterated tetrabenazine when administered orally to a subject. Increase in the total amount of AUC combined with dihydrotetrabenazine by at least 50%, or the half-life of deuterated dihydrotetrabenazine compared to a pharmaceutical composition containing the same amount of non-deuterated tetrabenazine. Said pharmaceutical composition that provides at least one of at least a 50% increase. [Selection figure] None |